



# Medi-Cal Rx Billing Policy for Continuous Glucose Monitoring Systems

---

April 21, 2022

The Department of Health Care Services (DHCS) has received reports of impeded access to **non-therapeutic** continuous glucose monitoring systems by providers asserting these products are a pharmacy benefit and billable to Medi-Cal Rx. This is incorrect. Non-therapeutic continuous glucose monitoring systems are not a pharmacy benefit and should not be billed as such to Medi-Cal Rx. Providers should bill these devices as a medical benefit, and medical claims should be submitted by the provider to a Managed Care Plan (MCP) as applicable.

Fee-for-Service (FFS) coverage policy for **non-therapeutic** continuous glucose monitoring systems has not changed since the implementation of Medi-Cal Rx on January 1, 2022.

Currently, only **therapeutic** continuous glucose monitoring systems are a pharmacy benefit billable to Medi-Cal Rx with an approved prior authorization (PA). Covered products are restricted to Dexcom G6 and Abbott Libre systems; only these products are reimbursable as a National Drug Code (NDC)-billed pharmacy item through Medi-Cal Rx.

For more information regarding therapeutic continuous glucose monitoring systems coverage as a Medi-Cal Rx benefit, please refer to the [List of Covered Therapeutic Continuous Glucose Monitoring \(CGM\) Systems](#) on the [Medi-Cal Rx Web Portal](#).

Medi-Cal MCPs must continue to cover and reimburse non-therapeutic continuous glucose monitoring systems as a medical benefit. Medi-Cal beneficiaries should not be directed to go to a pharmacy to obtain non-therapeutic continuous glucose monitoring systems.

Beneficiaries should contact their MCP directly for information and direction for acquiring these items as a medical benefit.